Thrombolysis in stroke patients; Problems and limitations

Iranian Journal of Medical Sciences

Volumn 35, Issue 2, 2010, Pages 145-148

  Ghandehari, Kavian ^a   Foroughipour, Mohsen ^a   Pourzahed, Ali ^a   Taheri, Marzieh ^a   Abbasi, Maryam ^a   Gorjestani, Shirin ^a   Ahmadi, Amir Moghaddam ^a   Nahayati, Mohammad Ali ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Iran; Thrombolysis; Tissue plasminogen activator

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BRAIN ISCHEMIA; CLINICAL DECISION MAKING; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; DISEASE SEVERITY; DRUG CONTRAINDICATION; DRUG COST; FEMALE; HEMODIALYSIS; HEPARINIZATION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; IRAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OBSERVATIONAL STUDY; PARTIAL THROMBOPLASTIN TIME; PATIENT TRANSPORT; PROSPECTIVE STUDY; TERTIARY CARE CENTER; THERAPY DELAY; X-RAY COMPUTED TOMOGRAPHY;

EID: 79959260667     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Durai Pandian J, Padma V, Vijaya P, Sylaja PN, Murthy JM.Stroke and thrombolysis in the developing countries. International J Stroke 2007; 2: 17-26
2. Nandigam K Narayan SK, Elangovan S, et al. Feasibilityof acute thrombolytic therapy for stroke. Neurol India 2003; 51: 470-3
3. Sobesky J, Frackowiak M, Weber OZ, et al. The Cologne stroke experience: safety and outcome in 450 patients treated with intravenous thrombolysis. Cerebrovasc Dis 2007; 24: 56-65
4. Adams HP, Del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke. Stroke 2007; 38: 1655-711
5. Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: The first prospective evaluation. Clin Neurol Neurosurg 2006; 108: 549-52
6. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004; 35: e27-9
7. Haung P, Chen CH, Yang YH, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. Cerebrovasc Dis 2006; 22: 423-8
8. White-Baterman SR, Schumacher C, Sacco RL, Appelbaum PS. Consent for intravenous thrombolysis in acute stroke. Arch Neurol 2007; 64: 785-7
9. Padma MV, Singh MB, Bhatia R, et al. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol India 2007; 55: 46-9
10. Pandian JD, Sethi V, Dhillon R, et al. Is intravenous thrombolysis feasible in a developing country? Cerebrovasc Dis 2005; 20: 134-6
11. Yu RF, San Jose MC, Manzanilla BM, et al. Sources and reasons for delays in the care of acute stroke patients. J Neurol Sci 2002; 199: 49-54
12. Ghandehari K, Pourzahed A, Taheri M, et al. Estimation of Iranian stroke patients eligible for intravenous thrombolysis with tPA. Int J Stroke 2009; 4: 236.